Meet us

Viravaxx will be presenting data from an interim analysis of its Hepatitis B vaccine candidate VVX001 at the following upcoming conferences:

  • AASLD (American Association for the Study of Liver Diseases), November 12-15, 2021, Anaheim, California, USA: AASLD 2021
  • HEP DART (Frontiers in Drug Development for Hepatology), December 5-9, 2021, Cabo San Lucas, Mexico: HEP DART 2021

Viravaxx’ Principal Investigators, Petra Munda and Peter Ferenci, both from MedUni Vienna, will present the latest data from the VVX001 study.